Skip to content

Efficacy of Combined Low- and High- Frequency Stimulation in Peripheral Muscle Function During Hemodialysis

Efficacy of Combined Low- and High- Frequency Stimulation in Peripheral Muscle Function During Hemodialysis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03779126
Enrollment
56
Registered
2018-12-19
Start date
2018-02-01
Completion date
2025-06-30
Last updated
2023-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Keywords

Chronic Kidney Disease, Electrical stimulation

Brief summary

Chronic kidney disease is a systemic disease that affects not only renal function, but also, several organs, bringing social, psychological and physical impact to the patients under this condition. Due to long periods of inactivity during hemodialysis, electrical stimulation becomes a feasible alternative for development physical activity in these patients. Objective: Assess the efficacy of combined low and high frequency electrical stimulation in peripheral muscle function during hemodialysis. Methods: A randomised double-blind clinical trial with chronic kidney disease patient's under hemodialysis, whose will be allocated in four groups: low frequency electrical stimulation (LF) ; high frequency (HF); low and high frequency (LHF); and sham electrical stimulation. The groups will receive quadriceps application bilaterally, for sixty minutes, three times a week, for two months. In the intervention groups will be used highest intensity tolerated by the individual, and in the sham will be maintained the minimum intensity after beginning of the perception of the electric current. The individuals will be evaluated for anthropometry, functional capacity, quality of life and biochemical parameters.

Detailed description

Patients in the present study will be submitted to an evaluation protocol that must be started after the consent of the responsible medical team, and the patient through the Informed Consent Term. On the first day, patients will be evaluated for their personal antecedents, life habits, inflammatory and nutritional status, quality of life, Medical Research Council (MRC) and biochemical markers. On the second day, anthropometry, body composition and functional capacity will be performed. On the third day, the muscular function will be assessed by isokinetic evaluation. After completing the evaluations, patients will be allocated into four groups: low frequency (LF), high frequency (HF), low and high frequency (LHF), and sham.

Interventions

DEVICEElectrical stimulation

1\) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.

Sponsors

Hospital Sirio-Libanes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The assessments will be conducted for a second investigator to ensure the blinding of first investigator. The subjects will be randomised in four groups (low frequency, high frequency, low and high frequency and sham stimulation) to ensure the blinding of participants.

Intervention model description

The subjects will be randomised in four groups: 1) low frequency electrical stimulation (LF), 2) high frequency (HF), low and High frequency (LHF), and sham. The subjects will receive electrical stimulation in quadriceps bilaterally for 60 minutes , three times per week, during two months.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic kidney disease * Classical hemodialysis * Over 18 years old * No pace maker * Without cognitive or motor deficit * No regular physical activity in the last six months

Exclusion criteria

* Abstention for more than two consecutive sessions or four in total * Inability to perform the tests

Design outcomes

Primary

MeasureTime frameDescription
Assess the improvement of muscle massEight weeksThe muscle mass will be assessed by electric bioimpedance
Assess the improvement of muscle strengthEight weeksThe muscle strength will be assessed using isokinetic by peak torque
Assess the improvement of muscle resistanceEight weeksThe muscle resistance will be assessed using isokinetic by fatigue index

Secondary

MeasureTime frameDescription
Correlate peripheral muscle function with body compositionEight weeksPeripheral muscle function will be assessed by isokinetic dynamometer and body composition will be assessed by bioimpedance (Fresenius)
Correlate peripheral muscle function with functional capacityEight weeksPeripheral muscle function will be assessed by isokinetic dynamometer and functional capacity will be assessed by six minute step test.
Assess the improvement of intervention in quality of lifeEight weeksThe quality of life will be assessed by kidney disease quality of life-short form questionnaire (KDQOL-SF).It is eighty questions about physical aspects, economical and psychological with 80 items. The range could be from 0 to 100. A less score reflect better quality of life.
Assess the improvement of intervention in functional capacityEight weeksFunctional capacity will be assessed using six minute step test
Assess the improvement of intervention in hemodialysis effusionEight weeksThe hemodialysis efficacy will be assessed by Kt/v
Correlate peripheral muscle function using medical research council score with nutritional statusEight weeksPeripheral muscle strength will be assessed by medical research council score. It is a score which measure the muscle strength in six plans of movement with range 0 to 60. Higher values represent a better outcome. The findings will be correlated with biomarkers (urea, creatinine, ferritin, lactate and insulin growth factor 1).
Correlate peripheral muscle function using hand grip with nutritional statusEight weeksPeripheral muscle strength will be assessed by hand grip strength. It is a measure the hand grip strength with range 0 to 120 pounds. Higher values represent a better outcome.The findings will be correlated with biomarkers (urea, creatinine, ferritin, lactate and insulin growth factor 1).

Countries

Brazil

Contacts

Primary ContactWellington PS Yamaguti, Phd
wellington.psyamaguti@hsl.org.br1133940200
Backup ContactIgor G Moraes, Ms
igor.gmoraes@hsl.org.br1133940200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026